Back to search

Article

Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting System

2026-08-26

Abstract excerpt

<title>Abstract</title> <p> <bold>Background.</bold> Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying as an on-target pharmacological effect. Independent pharmacovigilance analyses have reported that GLP-1 RAs account for a large share of impaired-gastric-emptying (IGE) reports in spontaneous databases (Huang et al., 2025; Tu et al., 2026). We sought to reproduce these observations a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
946741fc-dd13-578f-b6fd-32bbbfd82ea9
DOI
10.21203/rs.3.rs-9818062/v3
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemDOI 10.21203/rs.3.rs-9818062/v3
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System databaseSemantic proximity
Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity
Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity
The Adverse Event Atlas and Signal Consensus Index: A Multi-Source Pharmacovigilance PlatformSemantic proximity
Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity
Drug-induced glucose metabolism disorders: A disproportionality analysis based on the FAERS databaseSemantic proximity
Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity
Select a neighboring publication to make it the new centre.